title: [Clinical efficacy of Z-100 for the treatment of leukopenia caused by radiotherapy--a multi-center double-blind comparative study with inosine].
abstract: The clinical usefulness and the optimal dose of Z-100 for the treatment of leukopenia caused by radiotherapy for malignant tumors was evaluated in a double-blind study comparing 20 micrograms and 30 micrograms injections of Z-100 and inosine (Z-20, Z-30 and IN group, respectively). The effective rate according to the evaluation by the attending physicians was 67.4%, 79.1% and 48.9% in the Z-30, Z-20 and IN groups, respectively, with a significantly higher efficacy rate for the Z-20 group than for the IN group. The frequency of adverse reactions was 14.3%, 3.9% and 5.6% in the Z-30, Z-20 and IN groups, respectively, with the highest rate in the Z-30 group, but there was no significant difference among the three groups. The useful rate based on total evaluation considering the effective rate and the safety profile in each group was 60.8%, 77.3% and 46.8% in the Z-30, Z-20 and IN groups, respectively, with the highest rate in the Z-20 group showing significant difference from that in the IN group. The above data confirmed the clinical usefulness of Z-100 and suggested that the optimal dose was 20 micrograms twice weekly for Z-100.
authors.affiliation: Department of Radiology, Keio University School of Medicine.
authors.forename: S
authors.initials: S
authors.lastname: Hashimoto
authors.forename: T
authors.initials: T
authors.lastname: Ohkawa
authors.forename: Y
authors.initials: Y
authors.lastname: Takekawa
authors.forename: J
authors.initials: J
authors.lastname: Horiuchi
authors.forename: T
authors.initials: T
authors.lastname: Mori
authors.forename: S
authors.initials: S
authors.lastname: Amino
authors.forename: K
authors.initials: K
authors.lastname: Morita
authors.forename: Y
authors.initials: Y
authors.lastname: Tanaka
authors.forename: Y
authors.initials: Y
authors.lastname: Mochizuki
authors.forename: T
authors.initials: T
authors.lastname: Yanagisawa
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000368:Aged; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007288:Inosine / Q000627:therapeutic use*; D007564:Japan; D007970:Leukopenia / Q000188:drug therapy* / Q000209:etiology; D008055:Lipids / Q000627:therapeutic use*; D008297:Male; D008351:Mannans / Q000627:therapeutic use*; D008875:Middle Aged; D009369:Neoplasms / Q000532:radiotherapy; D011878:Radiotherapy / Q000009:adverse effects*
chemical_list: D000276:Adjuvants, Immunologic; D008055:Lipids; D008351:Mannans; C031208:specific substance maruyama; D007288:Inosine